An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2507 in Patients With Solid Tumours

Trial Profile

An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2507 in Patients With Solid Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs KA 2507 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms HDAC6i
  • Sponsors Karus Therapeutics
  • Most Recent Events

    • 18 Sep 2017 According to a Karus Therapeutics media release, the first patient has been dosed in this trial.
    • 16 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 09 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top